MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/bloodadvances.2023011741

Медицинская библиотека · Blood advances · 2024

Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia.

Stilgenbauer Stephan, Tausch Eugen, Roberts Andrew W, Davids Matthew S, Eichhorst Barbara, Hallek Michael, Hillmen Peter, Schneider Christof, Schetelig Johannes, Böttcher Sebastian, Kater Arnon P, Jiang Yanwen, Boyer Michelle, Popovic Relja, Ghanim Majd T, Moran Michael, Sinai Wendy J, Wang Xifeng, Mukherjee Nabanita, Chyla Brenda, Wierda William G, Seymour John F

Клиническое исследование II фазыМногоцентровое исследованиеСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Chromosome 17p deletion (del[17p]) is associated with poor prognosis in patients with chronic lymphocytic leukemia (CLL). Venetoclax is approved for treatment of previously untreated and relapsed/refractory (R/R) CLL, including patients with del(17p), based on the open-label, multicenter, phase 2 M13-982 trial (NCT01889186). Here, we detail the 6-year follow-up analysis for M13-982. A total of 158 patients with previously untreated (n = 5) or R/R (n = 153) del(17p) CLL received 400 mg venetoclax daily after initial ramp-up until progressive disease. After a median follow-up of 70 months, the best objective response rate (ORR) was 77% (21% complete remission [CR] and 49% partial remission [PR]), with a median duration of response (DOR) of 39.3 months (95% confidence interval [CI], 31.1-50.5). The median progression-free survival (PFS) was 28.2 months (95% CI, 23.4-37.6), and median overall survival (OS) was 62.5 months (95% CI, 51.7-not reached), with 16% of patients remaining on treatment after 6 years. Multivariable analysis did not identify statistically significant correlation between patient subgroups defined by clinical or laboratory variables and ORR or PFS. The most common grade ≥3 adverse events were neutropenia (42%), infections (33%), anemia (16%), and thrombocytopenia (16%). Post hoc comparative analyses of PFS and OS from treatment initiation, from a 24-month landmark, and by minimal residual disease status were performed between patients with del(17p) in the M13-982 and MURANO studies in the interest of understanding these data in another context. These long-term data show the continued benefits of venetoclax in patients with del(17p) CLL. The trial was registered at www.clinicaltrials.gov as #NCT01889186.

Для цитирования: Stilgenbauer Stephan, Tausch Eugen, Roberts Andrew W, Davids Matthew S, Eichhorst Barbara, Hallek Michael, Hillmen Peter, Schneider Christof, Schetelig Johannes, Böttcher Sebastian, Kater Arnon P, Jiang Yanwen, Boyer Michelle, Popovic Relja, Ghanim Majd T, Moran Michael, Sinai Wendy J, Wang Xifeng, Mukherjee Nabanita, Chyla Brenda, Wierda William G, Seymour John F. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia.. Blood advances. 2024. DOI: 10.1182/bloodadvances.2023011741.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.